Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.